|
|
|
|
| Personalized cancer vaccines are pushing immuno-oncology forward, but delivery and manufacturing hurdles still stand in the way. In this webinar, Cytiva explores how optimized ionizable LNPs can improve mRNA vaccine delivery, tolerability, and tumor response, while supporting small-scale clinical manufacturing strategies that help move PCV candidates from concept to clinic with greater confidence. Click here to learn more. |
|
|
|
|
A Q&A With Nerissa Kreher, MD | Engineered tRNAs target translation itself — correcting shared errors like premature stop codons at the ribosome — to restore functional protein and redefine precision medicine by mechanism, not diagnosis. | |
|
|
|
By Hannah Glazier and Miguel Edwards | For decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology. | |
|
|
|
By Ryan M. Williams | Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic. | |
|
|
|
By Anna Rose Welch, Advancing RNA | In our mRNA Hot Takes "Season Finale," Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to answer yet another loaded question: Are things in the U.S. for mRNA as bad as they truly seem? | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| With 1900+ attendees, TIDES USA, May 11-14, 2026, at Boston's Hynes Convention Center, is North America's leading forum for advancing oligonucleotide, peptide, mRNA, genome editing, and delivery innovations. This event bridges research to reality, fostering collaboration, and breakthrough solutions. Explore cutting-edge workshops, tracks, and exhibits while connecting with global pioneers like Robert Langer and Kiran Musunuru. Register early for any early bird savings and save an additional 10% with VIP code ADVRNA10 at checkout! |
|
|
.png){kind=logo}
